scholarly journals Challenges in lung cancer diagnosis during the outbreak of COVID-19

2020 ◽  
Author(s):  
chunhua xu ◽  
wei wang ◽  
li li ◽  
jiwang wang
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Needle Biopsy ◽  
Transbronchial Biopsy ◽  
Public Health Emergency ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer ◽  
Novel Coronavirus ◽  
Individualized Management

A pandemic of 2019 novel coronavirus diseases (COVID-19) outbreak is a major public health emergency that has spread in the fastest speed, and caused the most extensive infection world widely. Transbronchial biopsy (TBB) and computed tomography guided percutaneous needle biopsy (CTPNB) is the most common and significant method for the diagnosis of lung cancer. During the COVID-19 pandemic, the indications of TBB and CTPNB must be managed strictly. Therefore, it is extremely indispensable to perform meticulous and individualized management for lung cancer patients to protect the patients from COVID-19.

scholarly journals Challenges in Advanced Lung Cancer Diagnosis During the COVID-19 Pandemic

2021 ◽  
Vol 20 ◽  
pp. 153303382110507
Author(s):  
Chunhua Xu ◽  
Li Li ◽  
Wei Wang
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Needle Biopsy ◽  
Transbronchial Biopsy ◽  
Public Health Emergency ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer ◽  
Individualized Management

A pandemic of coronavirus diseases 2019 (COVID-19) outbreak is a major public health emergency that has spread in the fastest speed, and caused the most extensive infection world widely. Transbronchial biopsy (TBB) and computed tomography guided percutaneous needle biopsy (CTPNB) is the most common and significant method for the diagnosis of lung cancer. During the COVID-19 pandemic, the indications of TBB and CTPNB must be managed strictly. Therefore, it is extremely indispensable to perform meticulous and individualized management for lung cancer patients to protect the patients from COVID-19.

scholarly journals Effect of Comorbidity on Lung Cancer Diagnosis Timing and Mortality: A Nationwide Population-Based Cohort Study in Taiwan

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Shinechimeg Dima ◽  
Kun-Huang Chen ◽  
Kung-Jeng Wang ◽  
Kung-Min Wang ◽  
Nai-Chia Teng
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Population Based ◽  
Physician Visits ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Kaplan Meier ◽  
Diagnosis Of Lung Cancer

The effect of comorbidity on lung cancer patients’ survival has been widely reported. The aim of this study was to investigate the effects of comorbidity on the establishment of the diagnosis of lung cancer and survival in lung cancer patients in Taiwan by using a nationwide population-based study design. This study collected various comorbidity patients and analyzed data regarding the lung cancer diagnosis and survival during a 16-year follow-up period (1995–2010). In total, 101,776 lung cancer patients were included, comprising 44,770 with and 57,006 without comorbidity. The Kaplan–Meier analyses were used to compare overall survival between lung cancer patients with and without comorbidity. In our cohort, chronic bronchitis patients who developed lung cancer had the lowest overall survival in one (45%), five (28.6%), and ten years (26.2%) since lung cancer diagnosis. Among lung cancer patients with nonpulmonary comorbidities, patients with hypertension had the lowest overall survival in one (47.9%), five (30.5%), and ten (28.2%) years since lung cancer diagnosis. In 2010, patients with and without comorbidity had 14.86 and 9.31 clinical visits, respectively. Lung cancer patients with preexisting comorbidity had higher frequency of physician visits. The presence of comorbid conditions was associated with early diagnosis of lung cancer.

scholarly journals Cytological and histological diagnosis of lung cancer in Sardinia and Italy in the 1990s

2016 ◽  
Vol 67 (4) ◽  
Author(s):  
P. Pirina ◽  
M. Budroni ◽  
S. Esposito ◽  
S. Ostera ◽  
M.F. Polo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Cancer Registries ◽  
Histological Diagnosis ◽  
Cytological Diagnosis ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

Background. Up to 30-50% of all lung cancer cases remain without cyto-histological characterisation. The aim of our study was to evaluate retrospectively the proportion of histological and/or cytological diagnosis in patients with lung cancer in Sardinia. Methods. Data was gathered by consulting the hospital registers and case notes of individual patients released from hospital with a diagnosis of Lung Cancer at all medical centres throughout Sardinia. In gathering patients’ data, we focused our attention on cytological and histological procedures through which allowed the lung cancer was diagnosed. Cancer Registries data was utilised to compare our data with national and Sassari province data. Results. From 1991 to 1996 there was a total of 3146 lung cancer patients registered in Sardinia. 1902 patients (60.5%) had a histological diagnosis, 142 patients (4.5%) a cytological diagnosis while in 1102 patients (35%) the diagnosis was performed without any pathological validation. Conclusions. Our study has shown that lung cancer diagnosis is supported by pathological verification in 65% of cases while in remaining 35% of patients the diagnosis is based only on clinical and radiological reports. In Italy data from Cancer Registries report the percentage of cyto- histological diagnosis to be 70% with the percentage of cytological diagnosis being higher than in Sardinia.

scholarly journals Considering Patients’ Mental Capacity When Giving Them Bad News May Help Their Well-Being: A Case of Suicide Attempt after Being Informed of Lung Cancer Diagnosis

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Toshiyuki Kobayashi ◽  
Satoshi Kato ◽  
Mitsuo Takeuchi
Keyword(s):  
Lung Cancer ◽  
Suicide Attempt ◽  
Cancer Diagnosis ◽  
Attempted Suicide ◽  
Well Being ◽  
Mental Capacity ◽  
Bad News ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer ◽  
Mental Well Being

Mental capacity is a central determinant of patients’ ability to make autonomous decisions about their care and deal with bad news. Physicians should be cognizant of this when giving patients bad news in efforts to help them to cope with the illness and to avoid a deterioration of their mental well-being. To show the importance of this concept, a case of suicide attempt with lung cancer is exemplified. A 76-year-old woman attempted suicide after receiving a diagnosis of lung cancer. Her recent life had been emotionally turbulent and she did not have sufficient mental capacity to accept and cope with this truth. She developed depression before attempting suicide.

scholarly journals Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer

PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e11528
Author(s):  
Wen-Jun Zhu ◽  
Bo-Jiang Chen ◽  
Ying-Ying Zhu ◽  
Ling Sun ◽  
Yu-Chen Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Roc Curve ◽  
Lung Diseases ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Background MicroRNA-30a (miRNA-30a) levels have been shown to increase in the plasma of lung cancer patients. Herein, we evaluated the miRNA-30a levels in the bronchoalveolar lavage fluid (BALF) of lung cancer patients as a potential biomarker for lung cancer diagnosis. Methods BALF miRNA-30a expression of 174 subjects was quantified using quantitative real-time reverse transcription-polymerase chain reaction and compared between lung cancer patients and control patients with benign lung diseases. Moreover, its diagnostic value was evaluated by performing receiver operating characteristic (ROC) curve analysis. Results The relative BALF miRNA-30a expression was significantly higher in the lung cancer patients than in the controls (0.74 ±  0.55 versus 0.07 ±  0.48, respectively, p < 0.001) as well as in lung cancer patients with stage I–IIA disease than in those with stage IIB–IV disease (0.98 ±  0.64 versus 0.66 ±  0.54, respectively, p < 0.05). Additionally, miRNA-30a distinguished benign lung diseases from lung cancers, with an area under the ROC curve (AUC) of 0.822. ROC analysis also revealed an AUC of 0.875 for the Youden index-based optimal cut-off points for stage I–IIA adenocarcinoma. Thus, increased miRNA-30a levels in BALF may be a useful biomarker for non-small-cell lung cancer diagnosis.

scholarly journals Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules

2020 ◽  
Vol 146 (12) ◽  
pp. 3349-3357
Author(s):  
Yunli Huo ◽  
Zijian Guo ◽  
Xuehui Gao ◽  
Zhongjuan Liu ◽  
Ruili Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Predictive Value ◽  
Positive Test ◽  
Test Results ◽  
Newly Diagnosed ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Abstract Purpose Increasing lung cancer incidence in China with a high death rate due to late diagnosis highlights the need for biomarkers, such as panels of autoantibodies (AAbs), for prediction and early lung cancer diagnosis. We conducted a study to further evaluate the clinical performance of an AAb diagnostic kit. Methods Using enzyme-linked immunosorbent assay, levels of seven AAbs in serum samples from 121 patients with newly diagnosed lung cancer, 84 controls (34 healthy individuals and 50 patients with benign lung disease), and 100 indeterminate solid nodules, were measured. Participants were followed up until 6 months after a positive test result to confirm lung cancer diagnosis. Results The seven AAb concentration was significantly higher in lung cancer patients than in controls (P < 0.05). The seven AAb sensitivity and specificity for newly diagnosed lung cancer were 45.5% and 85.3%, respectively, while the seven AAb combined area under the curve (in lung cancer patients versus controls) was 0.660. Of the 28 patients with solid nodules with positive test results, 8 and 3 were diagnosed with lung cancer and benign lung disease, respectively, during follow-up. The positive predictive value of the experiment was 72.7%. Conclusion Positive AAb test results were associated with a high risk of lung cancer. The seven-AAb panel also had a high predictive value for detecting lung cancer in patients with solid nodules. Our seven lung cancer autoantibody types can provide an important early warning sign in the clinical setting.

scholarly journals Analysis of Lung Flute-collected Sputum for Lung Cancer Diagnosis

2015 ◽  
Vol 10 ◽  
pp. BMI.S26883 ◽  
Author(s):  
Jian Su ◽  
Nigar Anjuman ◽  
Maria A. Guarnera ◽  
Howard Zhang ◽  
Sanford A. Stass ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Early Stage ◽  
Polymerase Chain Reaction Analysis ◽  
Diagnostic Efficiency ◽  
Early Stage Lung Cancer ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Sputum Volume ◽  
Former Smokers

Molecular analysis of sputum can help diagnose lung cancer. We have demonstrated that Lung Flute can be used to collect sputum from individuals who cannot spontaneously expectorate sputum. The objective of this study is to further evaluate the performance of the Lung Flute by comparing the characteristics of parallel samples collected with and without the Lung Flute and the usefulness for diagnosis of lung cancer. Fifty-six early-stage lung cancer patients (40 current smokers and 16 former smokers) and 73 cancer-free individuals (52 current smokers and 21 former smokers) were instructed to spontaneously cough and use Lung Flute for sputum sampling. Sputum cytology and polymerase chain reaction analysis of three miRNAs (miRs-21, 31, and 210) were performed in the specimens. All 92 current smokers and 11 (28.7%) of 37 former smokers spontaneously expectorated sputum and also produced sputum when using the Lung Flute. Twenty-seven former smokers (70.3%) who could not spontaneously expectorate sputum, however, were able to produce sputum when using the Lung Flute. The specimens were of low respiratory origin without contamination from other sources, eg, saliva. There was no difference of sputum volume and cell populations, diagnostic efficiency of cytology, and analysis of the miRNAs in the specimens collected by the two approaches. Analysis of the sputum miRNAs produced 83.93% sensitivity and 87.67% specificity for identifying lung cancer. Therefore, sputum collected by the Lung Flute has comparable features as spontaneously expectorated sputum. Using the Lung Flute enables former smokers who cannot spontaneously expectorate to provide adequate sputum to improve sputum collection for lung cancer diagnosis.

scholarly journals Diagnostic Utility of Adenosine Deaminase in Serum and Bronchoalveolar Lavage Fluid for Screening Lung Cancer in Western Iran

2013 ◽  
Vol 32 (2) ◽  
pp. 109-115 ◽  
Author(s):  
Bahram Nikkhoo ◽  
Naseh Sigari ◽  
Bayazid Ghaderi ◽  
Abdolrahim Afkhamzadeh ◽  
Namam-Ali Azadi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adenosine Deaminase ◽  
Cancer Diagnosis ◽  
Bronchoalveolar Lavage Fluid ◽  
Screening Tool ◽  
Lavage Fluid ◽  
Control Group ◽  
Blood Samples ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Summary Background: This study aimed to determine adenosine deaminase (ADA) activity as a possible screening tool in lung cancer patients. Methods: Blood samples were collected from 30 subjects with positive pathological tests and 62 patients with negative pathological tests as a control group. The enzymatic activity of total ADA and its isoenzymes was determined. Results: tADA and ADA2 isoenzyme activity was significantly higher in cancerous patients compared to benign controls in serum and BAL fluid. Using a cut-off level of respectively 35.22 U/L and 31.80 U/L for BAL total ADA and ADA2, sensitivity and specificity were 100% and 81% for total ADA and 95% and 98% for ADA2. Conclusions: Adenosine deaminase may play important roles in the pathophysiology of lung cancer and because of its might be considered as a useful screening tool among the other markers in lung cancer diagnosis.

Concentration and integrity indexes of urine cell-free DNA as promising biomarkers for early lung cancer diagnosis

2021 ◽  
Vol 18 (2) ◽  
pp. 129-139
Author(s):  
Sai Ren ◽  
Xiaodong Ren ◽  
Haiqin Guo ◽  
Lan Liang ◽  
Kun Wei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Characteristic Curve ◽  
Healthy Controls ◽  
Cell Free Dna ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Free Dna ◽  
Pcr Targeting

Aim: To explore the role of urine cell-free DNA (ucfDNA) concentration and integrity indexes as potential biomarkers for lung cancer diagnosis. Materials & methods: Quantitative real-time PCR targeting Arthrobacter luteus ( ALU) repeats at three size fragments ( ALU-60, 115 and 247 bp) was performed in 55 lung cancer patients and 35 healthy individuals. Results: ucfDNA concentration and integrity indexes were significantly higher in lung cancer patients than in healthy controls. The area under the receiver operating characteristic curve for differentiating patients with stage I/II from healthy controls by ALU fragments concentration were 0.856, 0.909 and 0.932, respectively. In addition, the ucfDNA integrity indexes in patients with lymph node metastasis were significantly higher than in patients with non-metastatic. Conclusion: ucfDNA concentration and integrity indexes could serve as promising biomarkers for lung cancer diagnosis.

scholarly journals Ancillary Testing in Lung Cancer Diagnosis

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
William Dubinski ◽  
Natasha B. Leighl ◽  
Ming-Sound Tsao ◽  
David M. Hwang
Keyword(s):  
Lung Cancer ◽  
Molecular Diagnostics ◽  
Cancer Diagnosis ◽  
Targeted Therapies ◽  
Patient Management ◽  
Predictive Information ◽  
Lung Cancers ◽  
Pathologic Diagnosis ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

The pathologic diagnosis of lung cancer historically has relied primarily on morphologic features of tumors in histologic sections. With the emergence of new targeted therapies, the pathologist is called upon increasingly to provide not only accurate typing of lung cancers, but also to provide prognostic and predictive information, based on a growing number of ancillary tests, that may have significant impact on patient management. This review provides an overview of ancillary tests currently used in the pathologic diagnosis of lung cancer, with a focus on immunohistochemistry and molecular diagnostics.

Sign in / Sign up

Export Citation Format

Share Document